Phase IV, multicenter study to evaluate the correlation of the overall objective response according to RECIST criteria v1.1. assessed by conventional imaging techniques, the morphologic response by CT and pathologic response after the resectability of liver metastases secondary to colorectal cancer treated with bevacizumab in combination with XELOX
Latest Information Update: 13 Apr 2022
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms AVAMET
- 12 Sep 2017 Status changed from recruiting to completed, as per an abstract presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
- 23 May 2012 New trial record